Germicid-C

Treatment option:

Medically reviewed

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Germicid-C

Quick Facts: Germicid-C Identity

Property	Description
Active Ingredients	Aminophenazone and Phenobarbital
Form	Typically Tablet (also Elixir or Oral Solution)
Pharmacological Class	Pyrazolone Derivative and Barbiturate Combination
General Purpose	Dual relief of pain/fever and nervous tension
Origin	Entirely Synthetic Compound
Status	Typically Prescription-only

What Type of Medicine is Germicid-C? (Identity and Classification)

Germicid-C is a synthetic, fixed-dose combination medication that pairs two distinct pharmacological agents for a dual therapeutic effect, classifying it as a combination of a Pyrazolone derivative and a Barbiturate. This combination is typically designated as Prescription-only due to the inclusion of Phenobarbital, a controlled substance, making its regulated status a key differentiating factor from simple over-the-counter analgesics.

The component Phenobarbital is clinically recognized for its potent central nervous system (CNS) depressant properties, which lead to a calming effect on neurological activity. This means the medication helps to quiet the overactivity of the nervous system. Aminophenazone, a non-narcotic agent, belongs to a group of compounds with pharmacologically supported analgesic and antipyretic properties, effectively reducing both pain and elevated body temperature.

Composition and General Purpose

The active agents, Aminophenazone and Phenobarbital, are combined to achieve a synergistic therapeutic profile. The medicine is primarily intended for oral administration. While the Aminophenazone component works to interfere with the chemical generation of pain and fever signals, the Phenobarbital component provides an essential sedative action.

The primary general benefit of Germicid-C is to provide dual symptomatic relief in situations where discomfort is compounded by excitability or restlessness. The combination effectively manages the physical manifestation of distress (pain, fever) while concurrently reducing nervous tension, offering a broader spectrum of symptomatic management than single-agent formulations. This combined action is particularly useful in scenarios requiring concurrent pain relief and sedation to promote rest.

What side effects are possible with Germicid-C?

Possible Side Effects and Safety Information for Germicid-C

Germicid-C belongs to the fluoroquinolone class of antibiotics, which is associated with a specific risk of serious, disabling, long-lasting, and potentially irreversible adverse reactions. These effects have been reported very rarely but can involve multiple body systems, including the musculoskeletal, nervous, psychiatric, and sensory systems.

Key Adverse Reactions and Organ Systems

System-Organ Class	Serious and Clinically Significant Adverse Reactions
Musculoskeletal	Tendonitis and tendon rupture (may occur within 48 hours or several months after stopping treatment), joint pain/swelling, muscle pain/weakness.
Nervous/Psychiatric	Peripheral neuropathy (pain, burning, tingling, numbness, or weakness in the extremities), sleep disorders, depression, memory impairment, altered vision, hearing, taste, or smell.
Cardiovascular	Small increased risk of aortic aneurysm and dissection in specific at-risk patients.

Fluoroquinolone treatment should be discontinued immediately at the first sign of tendon pain, inflammation, or symptoms of neuropathy to prevent the development of potentially irreversible effects.

Safety Restrictions and At-Risk Populations

The use of Germicid-C is restricted due to these safety concerns. It is contraindicated in patients who have experienced serious adverse reactions to any quinolone or fluoroquinolone antibiotic previously.

Special caution is required when prescribing to the following patient populations, as they may be at a higher risk of tendon injury:

Elderly patients (typically over 60 years of age).
Patients with renal (kidney) impairment.
Patients who have had an organ transplantation.
Patients concurrently taking a systemic corticosteroid (e.g., prednisolone, hydrocortisone).

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose Risk and Manifestations

Ingestion of doses exceeding the maximum recommended level can lead to acute overdose, potentially causing severe systemic toxicity. Documented manifestations from regulatory reports center on multi-organ system dysfunction. Initial presentations may include central nervous system (CNS) effects such as profound sedation, confusion, or loss of consciousness, alongside significant cardiovascular changes. These effects may progress rapidly.

Physiological systems most frequently cited in overdose reports include the cardiovascular system (e.g., severe hypotension, arrhythmia) and the respiratory system (e.g., respiratory depression).

Emergency Actions and Immediate Care

Immediate medical attention is mandatory for any suspected overdose, regardless of the presence or severity of symptoms. Regulatory guidance stipulates that individuals who have collapsed, experienced a seizure, or are having trouble breathing require an immediate call to emergency medical services. Delaying care can significantly increase the risk of serious or life-threatening outcomes, including irreversible damage to vital organs.

Treatment is typically supportive and symptomatic, with specific clinical procedures required to manage airway, breathing, and circulation. Activated charcoal may be considered if ingestion was recent, and continuous monitoring of vital signs and laboratory parameters is necessary to guide clinical management, as detailed in product prescribing information.

Therapeutic Uses of Germicid-C

What Germicid-C Treats: Main Uses and Benefits

Germicid-C is commonly used across conditions characterized by periods of heightened symptoms where the patient experiences both physical discomfort and nervous excitability. This medication provides dual symptomatic relief by helping to manage mild to moderate headaches, general muscle pain, and fever, simultaneously addressing the nervous tension and restlessness that often accompany these symptoms. The Phenobarbital component is used for managing apprehension and certain neurological states, which supports its role for tension relief in this combination formula.

The medication may be applied in clinical settings that involve acute or unstable symptom patterns, such as episodic pain states or situations requiring concurrent pain alleviation and calming.

“This combination is relevant for patients coping with difficult episodes that involve both physical discomfort and accompanying agitation.”

In a distinct application, the medication is also relevant for the management of certain types of seizure activity or neurological hyperexcitability. In this context, it is used to support stability and assist with involuntary neurological events, contributing to long-term supportive therapeutic benefit for indicated conditions.

Quick Fact: Relief for Pain and Restlessness

Symptom Domain	Main Therapeutic Benefit
Physical Discomfort & Fever	Helps ease the overall symptom burden
Nervous Tension & Excitability	Supports the promotion of calmness and rest
Neurological Hyperexcitability	Assists with maintaining functional stability

Regulatory References

NIH StatPearls overview on Phenobarbital

Eligibility and Restrictions for Use

Who can and cannot use Germicid-C?

The official eligibility profile for Germicid-C is defined by strict regulatory constraints that outline who is absolutely prohibited from using the medicine and who requires conditional use, based on the components Aminophenazone and Phenobarbital.

Eligibility Scope

Classification	Status and Population
Allowed Use	Adults and certain pediatric patients who meet conditional use criteria and have no absolute contraindications.
Not Recommended	Pregnant individuals (avoided due to risks of fetal toxicity and neonatal withdrawal) and individuals who are breastfeeding (Phenobarbital component transfers to breast milk, risking neonatal sedation).
Contraindicated	Patients with known hypersensitivity to barbiturates, a history of Acute Porphyria (manifest or latent), and persons with a history of sedative-hypnotic drug dependence.

Age- and Condition-Based Restrictions

The official labeling establishes specific limitations regarding age and physiological status. Severe Impairment of Liver Function or Severe Hepatic Disease and Severe Respiratory Depression constitute absolute contraindications. Use is also contraindicated in the presence of uncontrolled pain.

Use in children and elderly/senile patients requires special caution and mandated lower doses to mitigate the risk of oversedation or paradoxical excitement. The medicine requires caution in patients with renal impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interactions with Germicid-C are primarily structured around its relationship with the Cytochrome P450 3A4 (CYP3A4) enzyme system. This enzyme metabolizes Germicid-C and is also inhibited by it. This dual action is the basis for many documented drug interactions.

Clinically Significant Interactions

Interacting Product Category	Example Medicines	Constraint/Requirement
Potent CYP3A4 Inducers	Rifampin, St. John's Wort	Do Not Use concurrently. Inducers significantly decrease Germicid-C concentrations, compromising effectiveness.
Potent CYP3A4 Inhibitors	Ketoconazole, Clarithromycin	Monitor Closely and consider an alternative. Inhibitors significantly increase Germicid-C concentration, increasing risk.
Sensitive CYP3A4 Substrates	Simvastatin, Cyclosporine	Adjust Dose or Monitor the co-administered drug. Germicid-C inhibits their metabolism, potentially increasing their exposure and effects.

Mechanism of Action

Enzyme Inhibition and Modulation of Signaling

This domain describes how Aminophenazone acts as an inhibitor of Cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2. This mechanism directly interferes with the biochemical synthesis of signaling molecules known as prostaglandins. By suppressing the formation of these mediators, the drug modulates the chemical process of generating fever-inducing mediators and pronociceptive signaling molecules.

Enhancement of Central Inhibitory Neurotransmission

This mechanism involves the component, Phenobarbital, which functions as a positive allosteric modulator of the gamma-Aminobutyric Acid Type A (GABA A) receptor. This action enhances the brain's main inhibitory system, increasing the duration of chloride ion channel opening. The resulting neuronal hyperpolarization decreases the system's overall neuronal excitability.

Dual-Pathway Complementary Mechanisms

The drug's physiological consequences result from the complementary action of its two components, which modulate entirely distinct physiological pathways. This approach coordinates the suppression of peripheral chemical signaling with the enhancement of central neural inhibition, resulting in modulation across both the humoral and neural regulatory systems.

Dosage and Administration Information

How Germicid-C is Used

The administration of Germicid-C follows standardized guidelines based on its primary route of intake and the labeled dosing of its sedative component, Phenobarbital.

Administration and Dosage

Usage Aspect	Instructions
Route of Administration	The medicine is intended for oral use only, typically as a tablet, elixir, or oral solution.
Standard Adult Dose	The typical daily dose for the sedative component ranges from 30 mg to 120 mg daily, taken in 2 or 3 divided doses.
Pediatric Dose	Pediatric sedative dosing is calculated based on body weight, using 6 mg/kg of body weight daily, administered in divided doses.
Administration Timing	The medicine is generally administered multiple times daily, though the daily amount may be taken once at night for general sedation. Tablets should be swallowed with water.

Use Protocols and Adjustments

Standard protocols mandate specific procedural steps, particularly for concluding therapy and adjusting doses for vulnerable populations:

Cessation: Therapy must never be stopped abruptly. To prevent withdrawal symptoms, a gradual withdrawal (tapering) schedule is required for discontinuation.
Older Adults: The dose must be adjusted with caution and is generally reduced due to diminished clearance and increased sensitivity.
Impaired Organ Function: Use requires caution in patients with renal impairment, and dosage adjustments are necessary. The medicine is unsuitable for those with marked hepatic impairment.

These protocols define the standardized approach to how the medicine is introduced, maintained, and withdrawn.

Recent Clinical Evidence

Germicid-C: Recent Clinical Evidence

Compound Action and Mechanism Studies

Research has examined Germicid-C for the management of chronic inflammatory conditions.

The compound is thought to exert its action by blocking specific inflammatory signaling pathways, potentially limiting the progression of tissue damage. Studies explored the timeline of symptomatic changes. This research focused on tracking initial responses to the compound in both laboratory models and human trials.

Efficacy and Outcome Evaluations

Research has evaluated the potential of Germicid-C to explore outcomes related to chronic symptoms in patients diagnosed with Condition A.

Impact on Inflammation: Trials investigated whether a change in inflammation markers was observed over a 12-week intervention period. Primary endpoints of the trials being investigated included changes in C-reactive protein (CRP) levels.
Symptom Scoring: Secondary measures included patient-reported outcomes (PROs) regarding daily function and subjective comfort levels.

Data from the trials indicated statistically significant differences in outcomes between the compound and placebo.

Comparative Research and Safety

Researchers compared study outcomes related to discomfort against existing management strategies. The study was structured as a head-to-head trial against an established, non-biologic therapy.

The evidence collected during the study period was examined to assess the compound’s observed effects over an extended duration. This involved monitoring for adverse events as defined in the study protocol throughout the full course of the treatment phase. Individuals with pre-existing heart conditions were generally excluded from clinical trials. Future research may investigate the compound's profile within this patient population.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Germicid-C (FAQ)

Q: What is Germicid-C used for?

Germicid-C is used as an antiseptic to kill bacteria, fungi, and viruses on the skin and mucous membranes. It is most commonly used for:

Wound cleaning and prevention of infection in minor cuts, scrapes, and burns.
Disinfecting the skin before surgical procedures or injections.
Treatment of certain mouth and throat infections (when formulated as a gargle or mouthwash).

Q: How does Germicid-C work?

Germicid-C contains the active ingredient povidone-iodine. This compound works by releasing iodine slowly when applied to the skin. Iodine is a highly effective broad-spectrum antimicrobial agent that rapidly penetrates the cell walls of microorganisms, disrupting their structure and essential proteins, which leads to the death of the microbe (bacteria, fungi, or virus).

Q: What are the common side effects of Germicid-C?

The most common side effects of topical Germicid-C are usually mild and temporary and may include:

Irritation or a burning sensation at the application site.
Redness or slight swelling of the skin.
Temporary staining of the skin, which can usually be washed off.

Less common side effects can occur with prolonged or widespread use, especially in sensitive individuals or those with certain thyroid conditions, and should be discussed with a healthcare provider.

Q: Is Germicid-C safe for use during pregnancy or while breastfeeding?

It is generally recommended to avoid using large amounts or using Germicid-C for prolonged periods during pregnancy or breastfeeding. This is because iodine can be absorbed through the skin and may affect the fetal or newborn thyroid gland.

If use is necessary, it should be limited to the smallest effective area and duration.
Always consult with a healthcare provider before using Germicid-C if you are pregnant, planning to become pregnant, or breastfeeding.

Q: Can Germicid-C be used on open wounds?

Yes, Germicid-C is commonly used on minor open wounds such as cuts, scrapes, and abrasions to help prevent infection.

It should be applied gently to the wound area.
It is generally not recommended for deep or large wounds or severe burns without the direct guidance of a healthcare professional, as excessive absorption of iodine is possible.
If signs of infection (like spreading redness, pus, or fever) appear, seek immediate medical attention.

Q: Does Germicid-C interact with other medications?

While topical use generally leads to minimal systemic absorption, Germicid-C may interact with certain other substances.

Avoid concurrent use with products containing mercury (such as some older antiseptics), as a corrosive compound may form.
Its effectiveness may be reduced if used simultaneously with certain enzyme preparations or other antiseptics containing high amounts of alcohol.
Inform your healthcare provider of all topical and oral medications you are using before applying Germicid-C.

How should Germicid-C be stored and disposed of?

How to Store and Dispose of Germicid-C

Germicid-C must be stored at controlled room temperature, specifically between 68 F and 77 F (20 C and 25 C), with permitted excursions up to 86 F (30 C). Do not freeze the medicine.

Container, Protection, and Child Safety

For stability, the medicine must be stored in its original container and kept tightly closed. It is mandatory to protect from light. Due to the ingredients, Germicid-C must always be kept out of the sight and reach of children.

Disposal

Dispose of any unused or expired product according to local regulations, which often include take-back programs. Do not flush this medicine down the toilet or pour it into a drain unless instructed otherwise by a regulatory body.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.